Skip to content
Baret News – Lifestyle
Author:
Aprea Therapeutics
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
November 5, 2026
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
November 4, 2026
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
October 20, 2026
Aprea Therapeutics to Present at October Conferences
October 8, 2026
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
September 22, 2026
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
August 12, 2026
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
June 1, 2026